Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) EPS (Basic) (2019 - 2026)

Vaxcyte (PCVX) has 8 years of EPS (Basic) data on record, last reported at -$2.3 in Q1 2026.

  • On a quarterly basis, EPS (Basic) fell 121.15% to -$2.3 in Q1 2026 year-over-year; TTM through Mar 2026 was -$6.88, a 72.43% decrease, with the full-year FY2025 number at -$5.63, down 48.16% from a year prior.
  • EPS (Basic) reached -$2.3 in Q1 2026 per PCVX's latest filing, down from -$1.8 in the prior quarter.
  • Over the last five years, EPS (Basic) for PCVX hit a ceiling of -$0.68 in Q1 2022 and a floor of -$2.3 in Q1 2026.
  • A 5-year average of -$1.13 and a median of -$1.02 in 2022 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): soared 43.96% in 2024, then plummeted 121.15% in 2026.
  • Tracing PCVX's EPS (Basic) over 5 years: stood at -$1.02 in 2022, then plummeted by 78.43% to -$1.82 in 2023, then skyrocketed by 43.96% to -$1.02 in 2024, then crashed by 76.47% to -$1.8 in 2025, then dropped by 27.78% to -$2.3 in 2026.
  • Business Quant data shows EPS (Basic) for PCVX at -$2.3 in Q1 2026, -$1.8 in Q4 2025, and -$1.56 in Q3 2025.